Multimode participation of traditional Chinese medicine in the treatment of COVID-19

Integr Med Res. 2021;10(Suppl):100781. doi: 10.1016/j.imr.2021.100781. Epub 2021 Oct 7.

Abstract

Background: The outbreak of COVID-19 has swiftly spread across China and all over the world, resulting in severe contagious pneumonia. However, no specific anti-COVID-19 drugs or methods are available for the treatment of this acute and fatal disease. In recent years, as the efficacy and safety of traditional Chinese medicine (TCM) have been universally acknowledged, it has been brought to a crucial status domestically and overseas for the treatment of COVID-19.

Methods: We searched relevant literature, electronic databases, and official statements, diagnoses and protocols to retrieve studies and applications related to traditional Chinese medicine for COVID-19 in terms of regulations and policies, clinical evidence, preclinical rationale and big data analysis and then summarized the discovery and development of potential drugs and their targets.

Results: Clinicians, researchers, governments, the public, colleges, institutes and companies collected and classified associated policies, regulations and actual contributions, searched clinical trials and preclinical experimental outcomes from databases, studied potential TCM drugs with possible mechanisms, retrieved numerous big data analysis method and gathered pooled results of compounds along with their effective targets to make traditional Chinese medicine vital to cover all stages of patients in the treatment and control of COVID-19.

Conclusion: Traditional Chinese medicine provides new evidence to support the clinical value of TCM for COVID-19.

Keywords: COVID-19; Multimode participation; Traditional Chinese medicine (TCM); Treatment.

Publication types

  • Review